Charles River Laboratories (CRL) FY2025 10-K Annual Report
Charles River Laboratories (CRL) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 18, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Charles River Laboratories FY2025 10-K Analysis
Business Overview
- • Core business model: Preclinical and clinical laboratory services for drug discovery and development
- • No new products, services, or business segments introduced or emphasized in this fiscal year
- • Maintained existing strategic practices, including strict compliance on timing of equity awards and insider trading policies
- • Fiscal 2025 equity awards policy with no stock options granted near earnings releases to avoid insider trading risks
- • No errors or clawbacks of executive compensation reported during or after fiscal 2025
Management Discussion & Analysis
- • Revenue DSA declined in fiscal 2025 due to lower study volumes; RMS revenue increased driven by large research models and pricing; Manufacturing Microbial Solutions grew robustly
- • Goodwill impairment of $165M in Biologics Solutions for 2025 due to reduced performance; impairment $215M in 2024 in same unit
- • Best segment: Manufacturing Microbial Solutions with robust growth, share gains, and higher sales; Worst segment: DSA with declined revenue and backlog falling to $1.9B from $2.0B
- • Capital allocation: Acquired KF for $510M, Noveprim controlling interest for $392.4M, SAMDI for $62.8M, PathoQuest option for ~$60M; acquisitions funded by cash and Credit Facility
- • Forward outlook: $300M cost savings by 2026; focus on strategic acquisitions, partnerships, and divestments of 7% 2025 revenue; cautious early-stage R&D spending remains a risk
Risk Factors
- • Cybersecurity risk governance by Board Audit Committee with quarterly reviews and direct CIO, CISO reporting to Audit Chair
- • Heavy reliance on Chief Information Officer with 30+ years experience for global IT risk oversight and digital strategy execution
- • Cybersecurity assessments include third-party audits, vulnerability tests, and industry standard compliance frameworks
- • Incident Response Plan mandates escalation to Audit Committee for significant cybersecurity events
- • No specific regulatory, geopolitical, operational supply chain, competitive, or financial risks detailed in this section
Charles River Laboratories FY2025 Key Financial MetricsXBRL
Revenue
$4.0B
▼ -0.9% YoY
Net Income
-$144M
▼ -750.1% YoY
Operating Margin
0.6%
▼ -499bp YoY
Net Margin
-3.6%
▼ -414bp YoY
ROE
-4.6%
▼ -520bp YoY
Total Assets
$7.1B
▼ -5.2% YoY
EPS (Diluted)
$-2.91
▼ -1555.0% YoY
Operating Cash Flow
$738M
▲ +0.4% YoY
Source: XBRL data from Charles River Laboratories FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Charles River Laboratories
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.